5-Amino-1MQ vs Lixisenatide

Head-to-head comparison of 5-Amino-1MQ (5-Amino-1-methylquinolinium) and Lixisenatide (Exendin-4-derived GLP-1 receptor agonist) — benefits, dosing, side effects, research data, and where to buy.

Research Score

Property5-Amino-1MQLixisenatide
CategoryWeight ManagementWeight Management
Full Name5-Amino-1-methylquinoliniumExendin-4-derived GLP-1 receptor agonist
Molecular Weight178.23 g/mol4858 Da
Half-Life~6 hours2-4 hours
Amino AcidsSmall molecule44
Typical Dose10-20 mcg daily
RouteSubcutaneous
Purity>98%≥98%
Studies Count28400
Research StatusActive ResearchApproved

5-Amino-1MQ Benefits

  • Reduces body fat without appetite changes, lowers cholesterol, increases NAD+ levels, improves metabolic efficiency, supports cellular energy production

Lixisenatide Benefits

  • postprandial glucose control
  • modest weight loss
  • appetite reduction
  • short-acting option

5-Amino-1MQ Dosing

Research doses: 50-150 mg orally daily. Often cycled 8-12 weeks on, 4 weeks off. Best taken in the morning.

Lixisenatide Dosing

10 mcg SC daily for 14 days|Increase to 20 mcg daily|Inject before the first meal of the day

5-Amino-1MQ Side Effects

  • Generally well-tolerated in preclinical models. Potential mild GI discomfort and headache. Long-term human safety data is limited.

Lixisenatide Side Effects

  • nausea
  • vomiting
  • hypoglycemia when combined with insulin

Research Overview

5-Amino-1MQ

Studies in diet-induced obese mice showed significant reductions in body weight, white adipose tissue mass, and cholesterol levels without changes in food intake. Works by inhibiting NNMT enzyme to increase NAD+ and activate sirtuins.

Lixisenatide

Lixisenatide produces small but measurable weight loss in diabetes trials while improving postprandial glucose excursions. Its shorter half-life makes it a useful reference compound for first-generation incretin mimetics.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

5-Amino-1MQ stacks with:

AOD-9604MOTS-cCJC-1295

Lixisenatide stacks with:

basal-insulinmeal-plan
weight-lossNNMT-inhibitorfat-lossmetabolismNAD+GLP-1RAshort-actingpostprandial-controlweight-loss-adjacent